INTRODUCTION
============

Sortilin-related receptor 1 (SORL1; also known as sorting protein-related receptor 1 and LR11) is a 250-kDa type-1 membrane protein of unknown function that is expressed in neurons of the central and peripheral nervous system ([@b11-0060424]; [@b41-0060424]; [@b9-0060424]; [@b23-0060424]). Although its function is still poorly understood, SORL1 is a member of a family of neuronal receptors that share structural similarity with yeast vacuolar protein sorting 10 protein (Vps10p), a sorting-specific polypeptide that transports carboxypeptidase Y from the Golgi to vacuoles ([@b18-0060424]). Interestingly besides its potential role in certain cancer pathways ([@b1-0060424]; [@b5-0060424]), SORL1 expression is reduced in brain tissues from individuals with Alzheimer\'s disease (AD) ([@b17-0060424]), suggesting a potential role in AD pathogenesis ([@b31-0060424]; [@b30-0060424]). The link between SORL1 and AD has been further strengthened by the recent demonstration that reduction of SORL1 expression promotes an increase of neurotoxic β-amyloid peptide (Aβ) formation by a mechanism that has been only partially elucidated ([@b2-0060424]; [@b35-0060424];

[@b24-0060424]; [@b38-0060424]). Indeed, the initial processing of amyloid precursor protein (APP) by α- and β-secretases is intimately associated with post-Golgi compartments and requires efficient transition of the precursor through these organelles ([@b8-0060424]; [@b40-0060424]). In this context, SORL1 interacts with APP and affects its trafficking and proteolytic processing in the brain, acting as a sorting receptor for APP holoprotein. By contrast, the absence or downregulation of SORL1 expression shifts APP holoprotein from the retromer recycling pathway to the β-secretase cleavage pathway, increasing secreted APPα (sAPPβ) production and, subsequently, Aβ formation ([@b29-0060424]; [@b13-0060424]).

The link between SORL1 and AD was also supported by the identification of AD-associated allelic variants in distinct regions of the *SORL1* gene in different populations. These results also suggested that these variants might map in still-unknown intronic regulatory regions that might govern cell-type- or tissue-specific expression of SORL1 ([@b3-0060424]; [@b10-0060424]; [@b14-0060424]; [@b15-0060424]; [@b22-0060424]; [@b31-0060424]; [@b34-0060424]; [@b16-0060424]; [@b39-0060424]; [@b21-0060424]). Thus, expression of these variants might affect AD risk by altering the physiological role of SORL1 in the processing of APP holoprotein ([@b32-0060424]).

In recent works, we have documented pivotal roles of pol-III-transcribed non-coding (nc) RNAs in gene expression regulation and, in particular, in the regulation of alternative splicing ([@b6-0060424]; [@b27-0060424]; [@b4-0060424]; [@b19-0060424]; [@b20-0060424]; [@b37-0060424]). A still uncharacterized transcription unit of our collection (hereafter referred to as 51A) maps to intron 1 of the *SORL1* gene (a genomic portion subjected to alternative splicing events) in antisense configuration. Thus, we hypothesised a possible control of *SORL1* pre-mRNA maturation mediated by 51A ncRNA expression. According to this working hypothesis, the synthesis of this ncRNA and its possible RNA:RNA pairing with *SORL1* pre-mRNA would mask canonical splicing sites, leading to alternative splicing events. By addressing such a hypothesis, in this work we demonstrate that: (i) 51A is a newly identified ncRNA whose synthesis promotes the expression of SORL1 alternatively spliced protein variants to the detriment of the canonical SORL1 splice variant A; (ii) this event triggers an altered processing of APP that leads to its impaired internalisation; (iii) this process ultimately leads to increased amyloid secretion; and (iv) 51A is upregulated in post-mortem cerebral cortices from individuals with AD.

###### TRANSLATIONAL IMPACT

**Clinical issue**

The mechanisms that cause Alzheimer\'s disease (AD) are still unclear. Rare familial forms of AD are clearly linked to mutations in a few genes (mainly involved in amyloidosis, such as those encoding APP and presenilins), but the genesis of sporadic forms is still obscure. There is therefore great interest in obtaining a deeper comprehension of disease mechanisms, and in particular the tightly regulated molecular events whose dysfunction is associated with neuronal death in AD. Recent data indicate that newly identified ncRNAs are overexpressed in the brains of AD subjects, where they modulate alternative splicing events that ultimately regulate amyloid formation. In this study, the authors investigated a previously uncharacterised ncRNA that maps within *SORL1*, a gene that encodes a receptor for apolipoprotein E (a well-known risk factor for late-onset AD) and that has been associated with AD. Allelic variants of *SORL1* have recently been associated with AD, and preliminary results suggest that the function of SORL1 is reduced in the disease.

**Results**

Here, the authors describe a new ncRNA (named 51A) that maps in an antisense orientation in intron 1 of the *SORL1* gene and whose synthesis promotes the expression of alternatively spliced SORL1 variants. The expression of 51A was detected in normal human brain samples, and was significantly overexpressed in AD brain. In vitro, 51A reduced the expression of SORL1 variant A while increasing the amounts of alternative isoforms. The expression of 51A also induced a significant increase in amyloid formation in cultured cells. Finally, the authors report a modest increase in the expression of 51A in post-mortem AD brains.

**Implications and future directions**

Based on their results, the authors hypothesise that abnormal regulation of *SORL1* by the ncRNA 51A might increase susceptibility to AD by increasing amyloid formation via downregulating SORL1 variant A. This work reveals a new mechanism by which an AD-associated gene might be regulated, and highlights the importance of ncRNAs in regulating amyloid formation and potentially neurodegeneration. Knowledge about ncRNA is limited, so further studies of the role of different ncRNAs in AD susceptibility are needed. Pursuing this issue could elaborate more details of the complex mechanisms involved in this disease and could lead to the identification of new therapeutic targets.

RESULTS
=======

51A is a newly identified PSE/DSE-dependent transcriptional unit
----------------------------------------------------------------

Alternative splicing variants of SORL1 with distinct biochemical properties have been reported (see [supplementary material Fig. S1](http://dmm.biologists.org/lookup/suppl/doi:10.1242/dmm.009761/-/DC1)), although the regulation of this phenomenon is still obscure. We have recently identified *in silico* 51A, a predicted transcriptional unit that maps to intron 1 of the *SORL1* gene in antisense configuration ([@b6-0060424]; [@b27-0060424]). Because intronic RNAs transcribed by RNA polymerase III (pol III) might regulate the splicing of protein-coding genes that are involved in AD ([@b19-0060424]; [@b20-0060424]), we hypothesised that the transcription of 51A might interfere with the maturation of *SORL1* pre-mRNA, leading to the occurrence of alternative splicing events that are potentially interesting for AD studies.

To test this hypothesis we first established the transcriptional activity of the 51A promoter by co-transfecting SKNBE2 neuroblastoma cells with a plasmid construct expressing a luciferase-silencing hairpin driven by the 51A promoter (hereafter referred to as pSHAG-51A) together with a plasmid expressing luciferase (pGL3). In this condition, if the 51A promoter is active, the transcription of the hairpin drives the post-transcriptional silencing of a co-transfected luciferase cDNA and the decrease of its signal; by contrast, an unaltered luminescent signal indicates that luciferase is not silenced because the 51A promoter is not active.

A reduced luminescence signal was detected in pSHAG-51A-transfected cells 48 hours after transfection (0.4±0.008 as normalised to cells transfected with pGL3 alone) as a consequence of efficient transcription of the silencing hairpin driven by the 51A promoter. In the same experiment, two well-assessed pol III type 3 promoters (U6 and H1 snRNA promoters) were used as positive controls driving the active transcription of the silencing hairpin, whereas a promoterless construct \[named No Promoter (NP)\] was referred to as the negative control because, as expected, it did not influence luciferase expression ([Fig. 1A,B](#f1-0060424){ref-type="fig"}). Altogether, these experiments demonstrate the transcriptional activity of the 51A pol III type 3 promoter.

![**The 51A transcription unit is actively transcribed in SKNBE2 cell nuclear extracts.** (A) Promoter activity transfection assay in human SKNBE2 cells. A specific luciferase-silencing hairpin is transcribed by the 51A PSE/DSE-dependent promoter. The promoter region encompasses the putative pol-III type 3 regulatory regions (TATA box, PSE and DSE). pGL3/pRL, negative control; pShag-NP, pShag-No promoter negative control; pShag-U6, positive control; pShag-H1, positive control; pShag-51A, sample of interest. (B) Sequence of the transcription unit. The PSE is in bold red and underlined, as is the putative T4 termination signal. A TATA-like element is also underlined. (C) In vitro transcription of plasmid-borne 51A (lane 3) or empty pNEB193 plasmid (lane 2) was carried out in a nuclear extract from SKNBE2 cells. The main 51A-specific transcripts are indicated by arrowheads on the right. The migration position of a 300-nt RNA size marker is indicated on the left. Lane 1, no DNA. (D) Primer extension analysis was conducted on unlabelled RNA products of in vitro transcription reactions programmed with no DNA (lane 1), empty pNEB193 plasmid (lane 2) or pNEB193-51A (lane 3). Shown in lanes 4-7 are the results of sequencing reactions conducted with the same 5′-labelled oligonucleotide utilised for primer extension. The sequence of the non-transcribed DNA strand around the TSS (+1) is indicated on the right. The position of the main, 51A-specific primer extension product is indicated by an arrowhead on the left.](DMM009761F1){#f1-0060424}

Next, to more directly test 51A RNA synthesis, we performed *in vitro* transcription of the 51A template, using a nuclear extract from SKNBE2 cells. As shown in [Fig. 1C](#f1-0060424){ref-type="fig"}, two main 51A-specific transcripts were produced. The shorter transcript approximately co-migrated with a 300-nucleotide (nt) RNA size marker. Such a transcript size was compatible with transcription initiating downstream of the proximal sequence element (PSE) (but upstream of the putative TATA-like element) and terminating at a run of four Ts ( T~4~) located \~300 bp downstream (evidenced in [Fig. 1B](#f1-0060424){ref-type="fig"}). The predominant 51A transcription product, however, was a longer transcript, whose size could be explained by pol III read-through at the T~4~ signal followed by termination at a downstream-located termination signal ([Fig. 1B](#f1-0060424){ref-type="fig"}). The transcription start site (TSS) of 51A was also investigated by primer extension analysis conducted on *in vitro*-produced, unlabelled transcripts. In both SKNBE2 ([Fig. 1D](#f1-0060424){ref-type="fig"}) and HeLa (not shown) cell nuclear extracts, a single predominant extension product, corresponding to transcription initiation at an A residue located 33 bp downstream of the start of the PSE, was observed. Such a short distance between PSE and the TSS is unusual, suggesting the possibility that other, still-uncharacterized *cis*-acting elements might influence 51A TSS selection.

51A transcription drives SORL1 alternative splicing
---------------------------------------------------

In order to test the possible influence of 51A synthesis on *SORL1* pre-mRNA splicing, we measured by real-time RT-PCR the expression of 51A RNA and *SORL1* splicing variants in different cell lines in order to identify an *in vitro* cellular model expressing both 51A RNA and *SORL1* variants. Results show that, with the exception of HeLa cells and NCTC-2544 (human skin keratinocyte), all examined cells express 51A RNA ([Fig. 2A](#f2-0060424){ref-type="fig"}). Similarly, *SORL1* variant A showed a rather ubiquitous expression profile, whereas the two alternatively spliced forms of *SORL1* \[variants B and F (see supplementary material Fig. S1 for details)\] are specifically expressed in SKNBE2 cells and are undetectable in all the other cell lines ([Fig. 2B-D](#f2-0060424){ref-type="fig"}). Therefore, because only the SKNBE2 cell line simultaneously expresses A, B and F protein variants, we used this cell line as a model to test possible variations of the relative amounts of these variants (by the means of protein variants ratio) induced by the overexpression of 51A ncRNA.

![**The overexpression of 51A ncRNA leads to SORL1 alternative maturation.** (A) 51A, (B) *SORL1* variant A, (C) *SORL1* variant B and (D) *SORL1* variant F RT-PCR expression profile in different cell lines. (E) RT-PCR expression analysis of 51A ncRNA and (F) *SORL1* variant A in 51A-transfected SKNBE2 cells and/or pMock controls; \*\* indicates statistical significance at *P*-values ≤0.01. (G) Western blot expression analysis of SORL1 variant A and B (or F) in 51A-transfected SKNBE2 cells. (H,I) Immunofluorescence detection of SORL1 alternatively spliced protein products. (H) Antibodies raised against the N-terminus of SORL1 protein form A show a clearly detectable signal in GFP-expressing cells only in the absence of a concomitant 51A overexpression, demonstrating the synthesis in this condition of the canonical protein form (1, GFP; 2, DAPI, 3, Tritch; 4, merge); three independent microscope fields are reported. (I) SORL1 variant A signal is absent or very weak in cells transfected with a construct co-expressing 51A and GFP: in this case, the transient overexpression of the ncRNA leads to the synthesis of the alternative forms of SORL1 endowed with a peculiar N-terminal portion that is not recognised by the same IgGs (1, GFP; 2, DAPI, 3, Tritch; 4, merge); three independent microscope fields are reported. Untransfected cells, which do not express GFP or 51A, are positive for SORL1, in accordance with a 51A-dependent change in the protein variant.](DMM009761F2){#f2-0060424}

Next, we tested whether the synthesis of 51A RNA might drive the splicing shift of *SORL1*. To this aim we transiently transfected SKNBE2 cells with a plasmid construct harbouring the whole 51A transcriptional unit (p51A-EGFPN1) and measured by real-time RT-PCR the amount of the individual *SORL1* splicing products (variants A, B and F). We found that, 48 hours after transfection, the increased synthesis of 51A RNA is accompanied by a strong decrease of the *SORL1* splice variant A mRNA content \[up to 5% of the original level (*P*=0.0002)\] ([Fig. 2E,F](#f2-0060424){ref-type="fig"}).

Next, taking advantage of a SORL1-specific antiserum raised against the C-terminal portion of the protein (that potentially recognises all the protein variants), we tested by western blotting whether the decrease of *SORL1* variant A transcription corresponds to a reduced amount of SORL1 protein. Results showed that an immunoreactive band of about 270 kDa (a size corresponding to the long canonical variant A) is significantly reduced (up to 14% of the original level) in 51A-overexpressing cells, confirming, at protein level, that the expression of 51A ncRNA favours the downregulation of the synthesis of SORL1 protein form A. Interestingly, in the same protein extract, a SORL1 immunoreactive band at about 110 kDa was upregulated in 51A-overexpressing cells, although at present it is not possible to ascribe its signal specifically to either variant B or variant F ([Fig. 2G](#f2-0060424){ref-type="fig"}).

Next, to further prove that the downregulation of SORL1 variant A is specifically induced by the synthesis of 51A RNA, we took advantage of a different SORL1-specific polyclonal antiserum raised against the N-terminal portion of splice variant A, thus ineffective to recognise the alternative protein forms B and F. By immunofluorescence microscopy we detected a marked signal of SORL1 in pMock-transfected cells; in this condition, 51A RNA is not overexpressed and the SORL1 variant A is predominantly synthesised and recognised by this antiserum ([Fig. 2H](#f2-0060424){ref-type="fig"}). By contrast, a strongly decreased signal was detected in cells overexpressing 51A RNA ([Fig. 2I](#f2-0060424){ref-type="fig"}). In this case, although we were unable to detect the increased synthesis of the alternative protein forms B and F (they harbour a different N-terminal portion and are thus not recognised by the antiserum), we found that overexpression of 51A RNA leads to a decreased amount of SORL1 variant A, which, as a consequence, is only barely detectable. In the same microscope fields, untransfected cells, which do not express GFP and 51A, were positive for SORL1, in accordance with a 51A-dependent change in the protein biochemical variant.

Altogether, the above results demonstrate that the synthesis of 51A RNA leads to the splicing shift of *SORL1*.

The 51A-dependent alternative splicing of *SORL1* leads to the impairment of Aβ secretion
-----------------------------------------------------------------------------------------

Because it has been demonstrated that the downregulation of SORL1 leads to the increase of Aβ formation, we hypothesised that the ability of 51A to specifically limit the synthesis of SORL1 variant A might also represent an upstream control of Aβ secretion. To address this hypothesis without the technical limitations imposed by the transient transfection procedure, we generated a transgenic SKNBE2 cell line permanently transfected with 51A expression plasmid (hereafter referred to as SKNBE2-51A). As a negative control we generated a SKNBE2 cell line permanently transfected with the empty vector (SKNBE2-Mock). In order to preliminarily characterise this experimental model, we measured, by real-time RT-PCR, the expression of 51A RNA and, by western blotting, the extent of SORL1 protein variant A downregulation. SKNBE-51A cells expressed 51A RNA at a 6.3-fold higher level than did SKNBE2-Mock cells and showed a parallel significant decrease in SORL1 protein content (*P*=0.0027) ([Fig. 3A,B](#f3-0060424){ref-type="fig"}). To evaluate the effects of 51A expression on the different SORL1 isoforms that cannot be discriminated by the antibody used in the western blot experiments, we analysed the amount of different *SORL1* mRNA variants in 51A-overexpressing cells by real-time RT-PCR. We found a decrease of *SORL1* variant A mRNA (*P*=0.0017) and a concomitant increase of variants B (*P*=0.003) and F (*P*=0.001) mRNAs in SKNBE2-51A cells as compared with SKNBE2-Mock cells, thus demonstrating that a prolonged overexpression of 51A RNA leads to the stable shift of *SORL1* splicing from the long form A to the alternative forms B and F ([Fig. 3C](#f3-0060424){ref-type="fig"}).

![**51A ncRNA overexpression and the consequent alternative splicing of SORL1 drive an impairment of amyloid release.** (A) RT-PCR analysis of 51A ncRNA expression in 51A permanently transfected SKNBE cells. (B) SDS-PAGE expression analysis of SORL1 variant A in 51A permanently transfected SKNBE cells. (C) RT-PCR analysis of *SORL1* variant A, B and F in 51A permanently transfected SKNBE cells. (D) Increased secretion of total Aβ, Aβ x-40 and Aβ x-42 in 51A-overexpressing SKNBE2 cells. *x*-axis: transfected plasmids. *y*-axis: quantitative determination of Aβ (pg/ml) secreted in the medium 48 hours after medium replacement as determined by sandwich ELISA (results were normalised to the pMock-transfected cell line).](DMM009761F3){#f3-0060424}

Considering that proteolytic processing of APP plays a central role in AD aetiology through the formation of Aβ ([@b12-0060424]; [@b33-0060424]) and that this processing is influenced by the downregulation of SORL1, we investigated whether the stable overexpression of 51A in SKNBE2 cells would affect the formation of Aβ. Hence, we measured by ELISA the relative amount of Aβ peptides ending at amino acid position 42 (Aβ x-42) and at position 40 (Aβ x-40) in the culture medium conditioned for 48 hours by SKNBE2-Mock or SKNBE2-51A cells. We found that the amount of both Aβ x-42 and Aβ x-40 is increased in SKNBE2-51A cells as compared with mock-transfected cells (1.35-fold, *P*=0.004 and 2.24- fold increase, *P*=0.001, respectively; [Fig. 3D](#f3-0060424){ref-type="fig"}). Therefore, these results demonstrate that, as expected, the overexpression of 51A and the consequent downregulation of SORL1 protein isoform cause a significant overproduction of Aβ.

51A RNA is overexpressed in AD post-mortem samples
--------------------------------------------------

In consideration of the role of 51A RNA in the regulation of amyloid formation in the *in vitro* model, we tested whether its expression might contribute to AD generation in *ex vivo* human brain samples. To this aim, we measured by real-time RT-PCR the amount of 51A RNA in cerebral cortices from 23 AD patients and 23 non-demented control samples. Interestingly, we found that 51A is actually expressed in human brains and that, although with significant individual variations, the average 51A expression is upregulated in AD samples (mean values: control=1.13; AD=2.14; *P*=0.049; [Fig. 4A,B](#f4-0060424){ref-type="fig"}). To verify whether the increase in 51A expression was specific for AD, we measured its expression in five samples of Parkinson\'s disease. The average level of expression (using *Top1* to normalise) was slightly higher than controls (1.13 versus 1.42) but much lower than observed in AD patients (1.42 versus 2.14). Although these results suggests a possible specificity of 51A overexpression in AD in comparison to other neurodegenerative diseases, owing to the small number of samples available they do provide any definitive conclusion, and larger studies will be required to assess this issue. Importantly, the differences in 51A expression observed in control versus AD patients were not related to the time of the sampling: we observed the lack of any relationship between the post-mortem delay of brain sampling and 51A expression (data not shown).

![**The expression of 51A is significantly increased in AD brains.** (A) 51A expression in AD cases (black columns) and non-AD control individuals (white columns) as determined by realtime RT-PCR of post-mortem cerebral cortex samples. (B) Box plot and median values are reported. Statistical analysis by Mann-Whitney U test demonstrated a significant difference between groups (*P*=0.049).](DMM009761F4){#f4-0060424}

The findings that SORL1 variant A is downregulated in AD and that there is a functional correlation between the expression of 51A and *SORL1* splicing (that leads to a decreased amount of the canonical variant A) clearly suggest that 51A RNA plays an active role in altering SORL1 expression in AD patients, leading to increased amyloid production that could ultimately induce neurodegeneration.

DISCUSSION
==========

In previous papers, we documented the relevant role of pol-III-transcribed ncRNAs in the regulation of alternative splicing in particular ([@b6-0060424]; [@b27-0060424]; [@b19-0060424]; [@b20-0060424]), and in the molecular events leading to neuron differentiation ([@b6-0060424]; [@b27-0060424]; [@b4-0060424]; [@b7-0060424]).

In the current work, we report the characterisation of a newly identified transcriptional unit, named 51A, that maps to intron 1 of the *SORL1* gene, and from which a newly identified regulatory ncRNA is synthesised. The expression of 51A leads to a splicing shift of *SORL1* mRNA that leads to the maturation of alternative protein forms instead of the canonical protein variant A. This event ultimately causes a significant downregulation of the canonical form of SORL1. Reduction of SORL1 expression has been shown to represent a condition that is associated with detrimental pathological consequences. In particular, SORL1 downregulation was reported to induce increased Aβ production ([@b2-0060424]; [@b35-0060424]; [@b24-0060424]; [@b38-0060424]). Thus, owing to its influence on SORL1 function, this ncRNA might be of particular relevance as a determinant of induction of Aβ-dependent neurodegeneration. We propose that triggering 51A RNA overexpression could represent one of the upstream regulatory events of Aβ generation.

Therefore, the results reported here support previous studies demonstrating that the downregulation of SORL1 drives the over-formation of Aβ and disclose a possible role of 51A as a newly identified regulatory element, acting upstream to Aβ formation via SORL1 variant A downregulation. In this context, the observation that a significant Aβ increase is observed in 51A-overexpressing cells whereas Aβ changes are more modest in SORL1 knockout (KO) mice ([@b2-0060424]) might plausibly be due to the different intensity of SORL1 downregulation observed in the two experimental systems, with the activation of compensatory pathways in KO animals that are not present in our transiently transfected cells.

It is also important to underline that 51A is expressed in non-AD human brains although at low levels, indicating a potential as-yet-unidentified physiological role for this ncRNA. Interestingly, the expression of 51A is significantly increased in AD brains (although with individual variations), suggesting that it might be involved in the Aβ generation in these individuals, through the inhibition of SORL1 expression. Currently, further experiments are needed to define the cause of the individual variation in 51A expression in post-mortem AD brains and possibly the correlation of this variation with clinical-pathological conditions such as, for example, brain inflammatory conditions. In any case, the reduction of Aβ production caused by 51A overexpression is associated with a reduction of SORL1 variant A content that could, in turn, affect Aβ production. Further studies are required to show a causative involvement of the 51A-dependent SORL1 modulation in the regulation of APP processing.

In conclusion, our results identify an active role played by a pol-III-transcribed ncRNA, acting upstream of Aβ formation via SORL1 variant A downregulation, in the control of amyloid processing, providing new insight into AD-related processes.

MATERIALS AND METHODS
=====================

Genomic and cDNA clones
-----------------------

The genomic clone herein analysed was generated following molecular biology procedures previously reported ([@b25-0060424]). The oligos used to generate the insert were 5′-ATGCATTAATTTAAGAGCAAGGACCTTGAT-3\', and 5′-ATGCATTAATTAGTGTATCATCAGTTGGCA-3\' and span a region containing the PSE/TATA pol III type 3 promoter together with the transcribed portion of 51A.

Human brain samples
-------------------

Frontal and temporal cortices from AD \[clinical history of disease; pathological diagnosis according to the Consortium to Establish a Registry for Alzheimer\'s Disease (CERAD) criteria\] and control cases (AD excluded by clinical neurological assessment and immunohistochemical analysis), as described in [Table 1](#t1-0060424){ref-type="table"}, derive from two different sources: the Brain Bank at Case Western Reserve University, Cleveland, OH, and the Joseph and Kathleen Bryan Alzheimer\'s Disease Research Center (Bryan ADRC) at Duke University Medical Center, Durham, NC. A total of 23 controls and 23 AD samples were analysed. Average age was 71 years for controls and 78 for AD brains.

###### 

Patient characteristics

![](DMM009761T1)

Cell culture, transfection and luciferase assay
-----------------------------------------------

Different cells lines were used: HEK-293, NCTC-2544, HepG2 and HeLa cells were maintained on Dulbecco\'s modified Eagle\'s medium (DMEM ECB7501L, EuroClone, Milan, Italy), 10% FBS (LONZA DE14-801F), L-glutamine (2 mM; EuroClone, Milan, Italy) and penicillin-streptomycin (100 U/ml/ 100 (ig/ml; EuroClone, Milan, Italy); Neuroblastoma cell lines (SKNBE2 and SHSY5Y) were maintained on RPMI 1640 medium (ECB9006L EuroClone, Milan, Italy), 10% FBS (LONZA DE14-801F), L-glutamine (2 mM; EuroClone, Milan, Italy) and penicillin-streptomycin (100 U/ml/ 100 (ig/ml; EuroClone, Milan, Italy; standard medium); LoVo cells were maintained on F-12K medium (LONZA BE12-615F), 10% FBS (LONZA DE14-801F), L-glutamine (2 mM; EuroClone, Milan, Italy) and penicillin-streptomycin (100 U/ml/ 100 (ig/ml; EuroClone, Milan, Italy). SKNBE cells were transfected using polyethylenimine (PEI; P3143, Sigma, St Louis, MO; 1 μg DNA2.5 μl PEI 10 mM) with pEGFP-N1 as control (referred in the text to as Mock) or pEGFP-N1-51A (referred to as 51A). G418 (Geneticin) was used in culture medium as a means of selection up to 1000 μg/ml, until resistant clones were identified. After selection the clones were preserved in 200 μg/ml G-418 in standard culture conditions. Luciferase-based promoter activity assay was performed 48 hours after transfection by firefly luciferase activity determination with the dual-luciferase reporter-assay system (Promega) according to the manufacturer\'s protocol.

Real-time quantitative RT-PCR analysis
--------------------------------------

Total RNAs from samples were extracted using TRIzol reagent (Invitrogen) according to the manufacturer\'s protocol and subjected to reverse transcription by Omniscript RT Kit (Qiagen, Valencia, CA, USA) as previously described elsewhere ([@b26-0060424]). The total RNA from samples was measured by real-time quantitative RT-PCR using PE ABI PRISM® 7700 Sequence Detection System (Perkin Elmer, Wellesley, MA, USA) and Sybr Green method following manufacturer\'s instructions. The sequences of 51A forward and reverse primers were 5′-TGGGA-GAGTCAGCATCTTGAAG-3\' and 5′-TGTACAGTCAGACAA-GAGGTGTGTGTAT-3\', respectively. The sequences of SORL1 (Var A) forward and reverse primers were 5′-AGCCCGAGCC-CATCAAG-3\' and 5′-AATCAGATGGTGGTGCACTGGG-3\', respectively. The sequences of SORL1 (Var B) forward and reverse primers were 5′-TTGGTTCTCGGCAGGTGAA-3\' and 5′-ATCT-GACAGCTCATACATCCTATGAGATT**-**3\', respectively. The sequences of SORL1 (Var F) forward and reverse primers were 5′-TCCTAGCATTTATTATTACTTTTCTCTCTTAA**-**3\' and 5′-GTAGCTAATCCAGATGGCGACTT-3\', respectively. For endogenous control, expression of the human glyceraldehyde 3 phosphate dehydrogenase (*G3PDH*) gene was examined. The sequences for human G3PDH primers were 5′-GAAGGTGAAG-GTCGGAGTC-3\' and 5′-GAAGATGGTGATGGGATTTC-3\'. Relative transcript levels were determined from the relative standard curve constructed from stock cDNA dilutions, and divided by the target quantity of the calibrator following the manufacturer\'s instructions. For the determination of 51A RNA expression in human post-mortem brain samples, we selected the appropriate housekeeping gene \[topoisomerase (DNA) I, NM003286.2\], taking advantage of the geNorm Housekeeping Gene Selection Kit as described elsewhere ([@b28-0060424]).

*In vitro* transcription analysis
---------------------------------

*In vitro* transcription reactions and primer extension experiments were carried out as previously described ([@b25-0060424]; [@b27-0060424]). To construct *in vitro* templates, a 51A-containing fragment was amplified from human genomic DNA and cloned into pGEM-Teasy vector (Promega) by using the primers 5′-ACAAACTCCATCTGCAATTCCTCG-3\' and 5′-CAGGTATAGGAGGGGTGCAGC-3\'.

Immunofluorescence detection
----------------------------

SKNBE2 cells were grown overnight on culture slides and then transfected with pEGFPN1-51A (or pEGFPN1 as control) using PEI (Sigma). At 48 hours after transfection the cells were washed in PBS, fixed for 10 minutes with 10% buffered formalin and blocked for 15 minutes with 3% BSA in PBS. Cells were subsequently incubated with primary antibody overnight at 4°C in 0.5% BSA in PBS. The next day, the cells were labelled with secondary antibodies for 45 minutes in 0.5% BSA/PBS solution. Cells were then incubated with DAPI for 5 minutes and mounted with Mowiol (Invitrogen) as described elsewhere ([@b36-0060424]). Immunostained cells were observed with the appropriate filters on an Axiovert 200 M (Zeiss, Jena, Germany) microscope and captured at the same adjustments of laser intensity and photomultiplier sensitivity using AxioVision software.

Primary antibody was anti-SorLA (H-300), sc-33822 rabbit polyclonal antibody raised against amino acids 86-385 mapping within an N-terminal extracellular domain of SorLA of human origin (Santa Cruz). Secondary antibody was anti-rabbit Rhodamine-TRITC (1:200; Jackson ImmunoResearch).

Aβ ELISA
--------

The amount of secreted Aβ x-40 and Aβ x-42 were evaluated by sandwich ELISA (IBL, Gumna, Japan) following the procedure here described. Media of 51A permanently transfected SKNBE2 cells were diluted in EIA buffer and processed using a kit specific for both Aβ species, following the indications of the manufacturer. The kits are solid-phase sandwich ELISA using plates pre-coated with the specific polyclonal anti-human Aβ antibody (raised against residues 38-42 or 35-40). An HRP-conjugated monoclonal human anti-Aβ antibody (11-28) was also supplied. Both assays show a linear reactivity within the range of concentration 7-1000 pg/ml for both Aβ species. Aβ concentration was determined using a Benchmark Microplate Reader and evaluated by Microplate Manager Version 5.1 software (Bio-Rad, Hercules, CA).

Western blot
------------

The proteins were quantified using a commercial protein quantification kit (Protein Assay, Bio-Rad) following the manufacturer\'s instructions. The samples were subsequently analysed by 10% SDS PAGE (SDS-PAGE) and transferred to a nitrocellulose membrane (Whatman, Inc., GE Healthcare, New York, NY) as previously described ([@b42-0060424]). In detail, the membranes were initially blocked by an incubation of 2 hours in Tris-buffered saline Tween 20 (TBST; 50 mM Tris-HCl, 150 mM NaCl, pH 7.5, 0.05% Tween 20) containing 5% non-fat dried milk. The blots were incubated for 1 hour with the appropriate primary antibodies: SorLA N-terminal (H-300, sc-33822, Santa Cruz) and anti-SORL1 C-terminal (Sigma-Aldrich, S9200). In order to normalise the protein levels of SORL1, western blot membranes were stripped with the stripping reagent 'Restore' (Pierce), then probed with a monoclonal antibody against α-tubulin (clone B-5-1-2; T 5168, Sigma; 1:2000). All primary antibodies were then diluted in TBS containing 0.1% NaN~3~ and 1% BSA. After washing with TBST, membranes were incubated with peroxidase-conjugated secondary antibodies \[anti-mouse IgGs (A 0168, Sigma; 1:12,000; anti-rabbit IgGs (A 0545, Sigma; 1:20,000)\] for 1 hour at room temperature. After washing, the reactive bands were revealed by ECL (Amersham Biosciences, GE Healthcare). Densitometric analysis of protein bands was performed using the ImageJ software system.

Statistics
----------

Experiments were performed in triplicate and repeated three times. Data are reported as mean value ± standard deviation, and statistical significance was examined using the unpaired Student\'s *t*-test. For analysis of 51A expression in control and AD brains, the non-parametric Mann-Whitney U test was used. *P*-values less than 0.05 were considered statistically significant.

In the figures, \* and \*\* indicate statistical significance at *P*-values of \<0.05 and \<0.01, respectively.
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